Everfront Biotech Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Everfront Biotech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma (NCT07349693) | Everfront Biotech Co., Ltd. | 2026-11-01 |
| A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer (NCT04381130) | Everfront Biotech Co., Ltd. | 2025-09-01 |
| To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers (NCT03651349) | Everfront Biotech Co., Ltd. | 2021-02-01 |
| A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma (NCT03234595) | Everfront Biotech Co., Ltd. | 2017-11-01 |
Track Everfront Biotech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.